Antiviral Nucleoside and Nucleotide Analogs: A Review | ||||
| Journal of Advanced Pharmacy Research | ||||
| Article 1, Volume 2, Issue 2, April 2018, Page 73-88 PDF (874.82 K) | ||||
| Document Type: Review Article | ||||
| DOI: 10.21608/aprh.2018.5829 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sawsan Mahmoud1; Sherifa Hasabelnaby1; Sherif Hammad1; Tamer Sakr  2, 3
| ||||
| 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Ein Helwan, Cairo, 11795, Egypt | ||||
| 2Radioactive Isotopes and Generator Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt | ||||
| 3Pharmaceutical Chemistry Department, Faculty of Pharmacy, October University of Modern Sciences and Arts (MSA), Giza, Egypt | ||||
| Abstract | ||||
| Virus infections are an increasing and probably lasting global risk. Nucleoside and nucleotide analogs represent the largest class of antiviral drugs. Early success in the treatment of human immunodeficiency virus infection and the recent approval of sofosbuvir as phosphoramidate nucleoside prodrug for chronic hepatitis C have provided proof of concept for important this class of compounds as an antiviral agent. This review summarizes the antiviral activity of nucleoside and nucleotide analogs and their recent application. | ||||
| Keywords | ||||
| Antiviral; Ebola virus; HCV; Nucleoside; Nucleotide; Zika Virus | ||||
|
Statistics Article View: 1,696 PDF Download: 4,532 |
||||
